Human parainfluenza viruses are the second main cause of hospitalisation of young children suffering from respiratory illness. Appropriate diagnosis can help personalize patient care and improve health outcomes. Human parainfluenza viruses (HPIVs) are enveloped RNA viruses responsible for upper and lower respiratory illnesses in all age groups. Although anyone can become infected, young children, older adults, and the immunocompromised are especially vulnerable.1 HPIVs often produce mild cold-like symptoms but can progress to severe clinical manifestations such as otitis media, pharyngitis, conjunctivitis, croup, tracheobronchitis, and pneumonia, which can result in life-threatening consequences.2
Reliable and timely diagnosis of respiratory pathogens can help differentiate among viruses, improve clinical decision making, and prevent viral outbreaks.
The cobas® Paraflu 1-4 UC Test for use with the cobas omni Utility Channel on the cobas® 6800/8800 Systems is a high-throughput multiplex assay for the qualitative detection and differentiation of respiratory viruses parainfluenza 1, parainfluenza 2, parainfluenza 3, and parainfluenza 4.
Flexible syndromic testing
Test what is medically relevant and necessary by customizing a targeted menu to address patient needs according to seasonality and geography.
Efficient, simultaneous workflow
Create time and cost savings by testing up to three respiratory assays from a single sample without batching nor pre-sorting.
Simplified and turnkey solution
Run fully compliant, CE-IVD workflow without further optimization. Positive and negative controls included.
Consolidated menu on high-throughput systems
Benefit from fully automated cobas® 6800/8800 Systems and an industry-leading menu to tackle seasonal high demand.
PPA = Positive Percent Agreement; NPA = Negative Percent Agreement CI = confidence interval; LCL = Lower confidence Limit; UCL = Upper confidence Limit
PPA = Positive Percent Agreement; NPA = Negative Percent Agreement CI = confidence interval; LCL = Lower confidence Limit; UCL = Upper confidence Limit
Target | Number of Samples (N) | Concordant Positive (N) | Discordant Positive (N) | Concordant Negative (N) | Discordant Negative (N) | Agreement Parameter | Percent Agreement (%) | 95% CI (LCL,UCL) |
HP1V1 | 222 | 55 | 1* | 163 | 3* | PPA | 94.8% | (85.9%, 98.2%) |
NPA | 99.4% | (96.6%, 99.9%) | ||||||
HP1V2 | 222 | 58 | 2* | 162 | 0 | PPA | 100% | (93.8%, 100.0%) |
NPA | 98.8% | (95.7%, 99.7%) | ||||||
HP1V3 | 221 | 30 | 0 | 190 | 1** | PPA | 96.8% | (83.8%, 99.4%) |
NPA | 100% | (98.8%, 100.0%) | ||||||
HP1V4 | 222 | 67 | 1* | 153 | 1** | PPA | 98.5% | (92.1%, 99.7%) |
NPA | 99.4% | (96.4%, 99.9%) |
References
1. Centers for Disease Control and Prevention. About Human Parainfluenza Viruses (HPIVs). https://www.cdc.gov/parainfluenza/about/index.html. Accessed 7 Jun 2021.
2. Branche, A. R., & Falsey, A. R. (2016). Parainfluenza Virus Infection. Seminars in respiratory and critical care medicine, 37(4), 538–554. https://doi.org/10.1055/s-0036-1584798